Herantis Pharma Plc, Press release, 12 January 2023 at 9:00 AM EEST
Link to the R&D update webinar (14:00-15:00 EET/13:00-14:00 CET): Click Here to Register
Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease-modifying therapies for Parkinson’s disease, will host an R&D update webinar on Thursday January 19th, 2023, for investors, analysts, media and for anyone interested in Herantis and our HER-096 program for Parkinson’s disease.
The agenda for Herantis’ R&D update webinar:
|Welcome and Introduction|
|Achivements during 2022|
|Why HER-096 is a perfect drug candidate for Parkinson’s disease (PD)|
|HER-096 animal data confirm its unique mechanism of action and brain penetration|
|Update on CDNF|
|Clinical development and biomarkers|
|Strategy and development milestones for 2023|
|Closing Statement & Q&A|
HER-096 is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein. HER-096 has demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, HER-096 has been shown to readily penetrate the blood brain barrier in preclinical studies allowing convenient subcutaneous dosing. Thanks to its multimodal mechanism of action, Herantis’ HER-096 has the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.
R&D Update Webinar Information:
Please join Herantis’ R&D update webinar on Thursday, January 19th, 2023 at 14:00– 15:00 EET via this link: Click Here to Register
After registering, you will receive a confirmation email containing information about joining the webinar. For more information and to access the live webcast, including audio, video and presentation slides, visit our web site at www.herantis.com .
The audience will have an opportunity to ask questions in a live Q&A session with speakers. Questions to event speakers may be asked beforehand by sending an e-mail to firstname.lastname@example.org. During the event, questions may be asked by using the chat function on the live webcast dashboard as well as by emailing email@example.com. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on www.herantis.com/investors/ following the conclusion of the event.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. As previously announced by Herantis, Nasdaq Stockholm AB has approved Herantis’ application to delist the shares of Herantis from Nasdaq First North Growth Market Sweden, and the last day of trading in the shares of Herantis on Nasdaq First North Growth Market Sweden shall be January 31, 2023.
For more information, please visit www.herantis.com